Lyra Therapeutics (LYRA) Current Deferred Revenue (2021 - 2025)

Lyra Therapeutics has reported Current Deferred Revenue for 5 years, with the latest figure at $11.9 million in Q4 2025.

• On a quarterly basis, Current Deferred Revenue fell 3.25% year-over-year to $11.9 million in Q4 2025; TTM through Dec 2025 was $11.9 million, a 3.25% decrease from a year earlier, with the FY2025 full-year figure at $11.9 million, down 3.25% from the prior year.
• Current Deferred Revenue was $11.9 million for Q4 2025 at Lyra Therapeutics, roughly flat from $11.9 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $16.2 million in Q1 2022, with the low at $9.8 million in Q3 2021.
• Average Current Deferred Revenue over 5 years is $13.3 million, with a median of $12.7 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Current Deferred Revenue jumped 56.11% in 2022, then decreased 12.57% in 2024.
• Over 5 years, Current Deferred Revenue stood at $11.7 million in 2021, then soared by 31.05% to $15.4 million in 2022, then declined by 10.15% to $13.8 million in 2023, then decreased by 11.12% to $12.3 million in 2024, then decreased by 3.25% to $11.9 million in 2025.
• The last three Current Deferred Revenue figures came in at $11.9 million (Q4 2025), $11.9 million (Q3 2025), and $11.9 million (Q2 2025), per Business Quant data.